There has been an increase in prescription of opioids for chronic non-cancer pain, and concern exists over possible diversion of prescription opioids to the illicit marketplace. Recent media coverage suggests that elderly patients sell their prescribed opioids for additional income. This study investigated the extent to which an Australian community sample of chronic pain patients prescribed opioids reported supplying their prescribed opioids to others. Design and Methods Participants living with chronic non-cancer pain and prescribed opioids for their pain (n = 952) were recruited across Australia via advertisements at pharmacies. A telephone interview included questions about their pain condition and opioid medication. Results Participants had been living with pain for a mean of 14.2 years; most common conditions included chronic back/neck problems and arthritis/rheumatism. Around half (43%) were currently prescribed one opioid, and 55% had been prescribed 2-5 opioids; the most common was oxycodone. Forty-two participants (4%) reported ever supplying prescribed opioids to another person; one participant reported receiving payment. Participants who supplied opioids to others were younger (odds ratio 0.97, 95% confidence interval 0.95-0.99) and engaged in a greater number of aberrant behaviours relating to their opioid medication (odds ratio 1.77, 95% confidence interval 1.45-2.17), including tampering with doses, taking opioids by alternative routes, seeing doctors to obtain extra opioids and refilling prescriptions early. Discussion and Conclusion Few people with chronic non-cancer pain divert their opioids to others. Media reports of elderly patients selling their opioids to supplement their income may be reflective of exceptional cases. Future studies may investigate the extent to which other patient groups divert prescription opioids to the illicit marketplace.
Introduction
In the past decade there has been an increase in prescribed opioids for chronic non-cancer pain, [1] [2] [3] [4] with concern over concomitant increases in dependent use and overdose. 1 2 5 This concern has arisen in parallel with concerns about the appropriateness of opioids in the longer term for the management of chronic non-cancer pain, 6 in contrast to acceptance of opioids as 'essential medicines' for the management of cancer pain. 7 Opioids are one of the most frequently borrowed and shared prescription medications [8] [9] [10] .
Research suggests that the majority of people within the general population who borrow prescription opioids obtain them from a family member or friend. 11 14 In an Australian survey of drug treatment clients that reported regular non-medical pharmaceutical use 12 over a third of the sample gave away opioids prescribed for them. Further, among this sample most pharmaceutical opioids used over the four weeks prior to entry into treatment were not sourced directly from a prescriber, but were bought from a friend, from the illicit market, or were a gift from a friend or partner. There has therefore been concern over the possibility that there is diversion of prescribed opioids from patients to the illicit market, which may be partially driving extra-medical use and dependence. 13 14 Media coverage suggests elderly patients prescribed opioids for chronic pain sell them to supplement their income, referred to as "fossil pharming". 15 16 There is limited data on this issue, and existing data on the extent to which elderly chronic pain patients provide opioids to others has been mainly qualitative. 17 However the possibility that older people are diverting their opioids to the illicit market is of concern given that, for example, Australian people aged 60 years and older receive around two thirds of morphine prescriptions, and three quarters of oxycodone prescriptions. 1 To further address this possibility, we investigated the extent to which people living with chronic pain supplied their prescribed opioids to others, using data from an Australian community sample.
Methods
The data reported here are from the first 952 participants recruited into the Pain and Opioids IN Treatment (POINT) cohort (http://ndarc.med.unsw.edu.au/project/point-studypain-and-opioids-treatment). This study is intended to follow participants at multiple points over a two year period. The major aims of the study are to examine the natural history of prescribed opioid use; examine the predictors of adverse events; and identify factors that predict poor self-reported pain relief and other outcomes. This study received ethical approval from the University of New South Wales.
With National Pharmacy Guild approval, we contacted 2,915 pharmacies from a national database of Australian pharmacies. All Tasmanian pharmacies were sampled first, followed by a random sample of pharmacies from NSW and then across Australia. Research staff contacted each selected pharmacy via phone to a) briefly explain the study and b) ask whether they would help with study recruitment.
Of the pharmacies selected, 1,121 (38%) agreed to help with recruitment. The spread of pharmacies mirrored the geographic distribution of the Australian population. Pharmacists that assisted with recruitment asked customers that had been prescribed a schedule 8 opioid (i.e., drugs of dependence that are subject to additional regulatory controls regarding their manufacture, supply, distribution, possession and use 18 ) if they would be interested in taking part in a study on pain and opioids. Pharmacists were reimbursed $20 for each eligible customer that was referred to the study. Interested people were invited to contact, or send in their contact details to the study team. The research team assessed each interested person's eligibility and explained the study in full before gaining voluntary informed consent to participate. As the current study was part of a large survey (encompassing the aims outlined in the previous paragraph) participants were not specifically told that the interview would include questions regarding diversion of their medication, nor was this the focus of the questions that were asked. It was explained to participants that their data would be kept confidential and would not be shared with anyone outside of the research team unless they threatened harm to themselves or others (as required by university ethics). Participants were given the option to decline to answer any of the questions throughout the interview.
Eligible participants were those who met the following criteria: a) English speaking, b) prescribed opioids (e.g., oxycodone) for 6 weeks or more, c) living with chronic pain (defined as pain for three months or longer), d) no current cancer, and e) not currently undergoing opioid substitution treatment for the management of opioid dependence developed through illicit opioid use. Telephone interviews with participants were conducted by trained interviewers with a minimum of four years undergraduate training in psychology.
Participants were reimbursed for their time ($40).
Questions used in this analysis included demographics such as age, gender and weekly income, current pain medication, number of opioid medications currently prescribed and the duration of current opioid treatment episode. Participants were also asked whether they had ever supplied or offered prescribed opioids to others (yes/no), if so, how frequently, how long ago, whether they received payment, and to whom they supplied/offered prescribed opioids.
All participants were asked questions regarding aberrant opioid-related behaviours over the past three months, using the Opioid Related Behaviours in Treatment scale (ORBIT) 19 . The scale comprises 10 items (e.g., 'Over the past 3 months, I have asked my doctor for an increase in my prescribed dose') and each item was scored dichotomously (yes/no) in the current study. The ORBIT scale was developed for use among Australian patients receiving opioid therapy for pain or opioid dependence in both clinical and research settings. The scale has demonstrated strong internal consistency (Cronbach's alpha = 0.85). 19 
Results
Of the 1778 individuals referred to the study by pharmacists, 472 (27%) were ineligible. Of the remainder, 952 participated (53%, 73% of eligible participants), 228 declined to take part in the study (13%, 17% of eligible participants), and 106 felt they were too unwell to take part in the study (6%, 8% of eligible participants). Fifty-one participants were eligible but had not completed their baseline interview at the time of this study.
The sample was approximately half male (44.5%) with a mean age of 58 years (range 19-89).
Participants had been living with chronic pain for a mean of 14.2 years (SD =12.4); just under three quarters (70.7%, n =296) had two or more current pain conditions. The most common pain conditions included chronic back or neck problems and arthritis/rheumatism. Around half the sample were currently prescribed one opioid (n =403), the other half were prescribed two to five opioids (n =528). The most commonly prescribed opioid was oxycodone (see Table 1 ).
Table 1 about here
As observed in Table 2 , 42 participants (4%) reported ever supplying/offering prescribed opioids to another person. Most participants reported doing so on one to 12 occasions, with median of 2 times, and a median of 6 months ago (range 1-276 months). One participant supplied prescribed opioids to their partner more than 100 times (no payment). Participants reported offering prescribed opioids to a partner (n=7), relative or friend (n=21) and three participants refused to specify. One participant reported receiving payment for supplying their friend prescribed opioids on four occasions. More than half of the participants who supplied/offered prescribed opioids (26 of 42 participants) were prescribed oxycodone; those who supplied/offered others their prescribed opioids were more likely to be currently prescribed hydromorphone (n=5, 11.9%) than participants who did not report such behaviour (n=37, 4.1%). Table 1 , participants who reported supplying/offering prescribed opioids were significantly younger; only 11 participants over 65 years reported supplying/offering prescribed opioids to others. Participants who supplied/offered prescribed opioids were no more likely to be male or female. Further, participants on a lower income (i.e., $0-399) were no more likely to have supplied/offered prescribed opioids compared to participants on higher incomes.
As seen in

Table 2 about here
As observed in Table 1 , the two groups did not differ with regard to the length of time they had been prescribed opioids. However, participants who reported supplying/offering their prescribed opioids to others were currently prescribed a significantly greater number of opioids (M = 2.05, SD = 0.85) than those who did not (M = 1.67, SD = 0.79, OR 1.70, 95% CI 1.20-2.40).
Participants who supplied/offered opioids also endorsed more aberrant opioid medication behaviours on the ORBIT scale (M = 1.61, SD = 1.97) compared to participants who did not (M = 0.53, SD = 0.90; OR 1.77, 95% CI 1.45-2.17; Table 1 ). Considering the individual ORBIT items ( Table 3 ), in comparison with participants who did not report supplying/offering their prescribed opioids to others, participants who did were significantly more likely to: a) ask their doctor for an early renewal of their prescription because they had run out early (26% vs. 10.1%; OR 3.17, 95% CI 1.54-6.51), b) go to a different doctor to get their opioid medication without telling their normal doctor (4.8% vs. 0.9%; OR 5.59, 95% CI 1.15-27.20), c) alter their dose, e.g. cutting patches or pills in half when not advised to do so (21% vs.4%; OR 6.21, 95% CI 2.77-13.89), and d) take their opioids by a different route than prescribed (e.g. injecting) (9.5% vs. 0.3%; OR 31.58, 95% CI 6.83-146.09). 
Discussion
Our study suggests that it is uncommon for people living with chronic pain to sell prescribed opioids to supplement income, or to offer it to others, and those who do supply/offer opioid medications to others, do so infrequently. Four percent of participants (42 out of the sample of 952) had ever engaged in medication sharing, and those that had supplied/offered their medication reported doing this a median of 2 times in their lifetime. A review of opioid related diversion suggests that several pathways of prescription opioid diversion exist including theft, doctor shopping and fraud 20 . Further, rates of diversion from other sources, for example college students prescribed opioids for acute pain conditions, have been found to be as high as 29 percent (50 of 171 participants) 21 . The smaller number of participants who diverted within the current study may indicate that other populations could be providing a larger amount of opioids to the illicit market place and future studies could aim to further investigate diversion within these groups.
With respect to the suggestion that elderly people may be likely to supply/offer their prescribed opioids to others, participants who did report such behaviour were significantly younger compared to those who did not, and only 11 were aged over 65 years. Over half the participants who reported supplying/offering prescribed opioids were on a lower income, however this was reflective of the sample as a whole. Only one participant reported receiving payment for their prescribed opioids. Rather, participants in the current study typically offered prescribed opioids to a family member or friend. Such findings are consistent with previous research that suggests the majority of people who borrow prescription opioids obtain them informally 11 12 22 .
Participants who reported supplying/offering their prescribed opioids to others endorsed a significantly greater number of aberrant behaviours, which included early renewal of their opioid prescriptions, seeking opioids from more than one doctor, tampering with their dose and taking opioids by a different route than prescribed. It seems that those who are willing to supply/offer their prescription opioids to others are less likely to follow doctors' recommendations in general with regards to their medication.
Our study provides a preliminary indication of the characteristics of chronic pain patients who divert their prescribed opioids. There was a small proportion of participants who diverted their medication (4%). Although there was no corroborative evidence to indicate that participants were reporting truthfully about their sharing of prescription opioids, they were informed that their responses would be de-identified and confidential; this has traditionally resulted in valid reports around illicit drug use. 23 Further, participants had nothing to gain from misrepresenting their behaviours, increasing the reliability of selfreport in this context. 24 While, there were no consequences to participants for disclosing diversion activities, it may be that people who engaged in such activities declined to take part in the study altogether due to fear that their responses may filter back to their pharmacy or legal authority. The chronic pain population within the current study is similar in terms of characteristics (i.e., age, gender distribution, length of time prescribed opioids, number of opioids prescribed) to other studies of chronic non-cancer pain patients, suggesting that our sample may not be overly biased in this regard. 25 26 It is possible that the results may have been affected by social desirability bias, whereby some chronic pain patients were reluctant to report supplying or offering their prescribed opioid. However, rather than diverting medications for financial gain, it appears most instances of medication sharing were giving their medication to family members or friends in an attempt to be helpful, which may not necessarily be perceived as socially undesirable.
Media reports 15 16 and previous research 4 indicating that elderly people are an important source of prescription opioids for the illicit market is not consistent with our findings. Our sample of people who were living with chronic pain did not appear to be engaging in considerable diversion. This may not be surprising given that they have current pain, and might be expected to prefer to use opioids to assist with management of this pain. This does suggest that a more important source of illicit opioids may be from patients who do not regularly need opioids for pain, or other sources. It seems clear that given the apparent scale of prescription opioid misuse among illicit drug users in Australia (e.g., 27 ), that there must be considerable diversion occurring from other channels. Further research is needed to understand how prescribed opioids are diverted to the illicit marketplace. 
